Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.
Serum prostate specific antigen was determined (Yang polyclonal radioimmunoassay) in 45 patients after anti-androgen therapy for stage D2, untreated adenocarcinoma of the prostate. Of the patients 9 per cent had undetectable prostate specific antigen levels and 22 per cent were within the normal range (0.0 to 2.5 ng. per ml.), with a mean interval of 2 years since introduction of therapy. Multiple prostate specific antigen values following anti-androgen therapy were available in 36 of 45 patients. The majority of the patients demonstrated an initial, often dramatic decrease in prostate specific antigen levels during the first 6 months after introduction of therapy. After 6 months 21 of 29 patients (72 per cent) had increasing prostate specific antigen levels. Data suggest that serum prostate specific antigen determination 6 months after introduction of therapy is capable of distinguishing patients with a favorable and persisting response to anti-androgen therapy from those in whom a limited response can be expected.
Stamey
T A
TA
Division of Urology, Stanford University Medical Center, California 94306-5118.
Kabalin
J N
JN
Ferrari
M
M
Yang
N
N
D000230:Adenocarcinoma / Q000097:blood* / Q000628:therapy; D000328:Adult; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000097:blood*; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000097:blood* / Q000628:therapy; D011863:Radioimmunoassay; D013997:Time Factors
D000726:Androgen Antagonists; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004054:Diethylstilbestrol; D017430:Prostate-Specific Antigen